Erratum: PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer (Science Translational Medicine DOI: 10.1126/scitranslmed.aaa4442);PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer

Science Translational Medicine

Volumn 7, Issue 283, 2015, Pages

  Bosch, Ana ^a,j   Li, Zhiqiang ^a   Bergamaschi, Anna ^b   Ellis, Haley ^a   Toska, Eneda ^a   Prat, Aleix ^c,d   Tao, Jessica J ^e   Spratt, Daniel E ^a   Viola Villegas, Nerissa T ^a,k   Castel, Pau ^a   Minuesa, Gerard ^a   Morse, Natasha ^a   Rodón, Jordi ^f,g   Ibrahim, Yasir ^f   Cortes, Javier ^f   Perez Garcia, Jose ^f   Galvan, Patricia ^c   Grueso, Judit ^f   Guzman, Marta ^f   Katzenellenbogen, John A ^h   Kharas, Michaelz ^a   Lewis, Jason S ^a   Dickler, Maura ^a   Serra, Violeta ^f   Rosen, Neal ^a   Chandarlapaty, Sarat ^a,i   Scaltriti, Maurizio ^a   Baselga, José ^a,i   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^c VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

^e HARVARD MEDICAL SCHOOL   (United States)

^f Genomics Cancer Group   (Spain)

^g UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^h UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

ⁱ WEILL CORNELL MEDICAL COLLEGE   (United States)

^j LUND UNIVERSITY   (Sweden)

^k KARMANOS CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPELISIB; BUPARLISIB; COPANLISIB; ESTRADIOL; ESTROGEN RECEPTOR; EXEMESTANE; FULVESTRANT; GROWTH REGULATION BY ESTROGEN IN BREAST CANCER 1 PROTEIN; LETROZOLE; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PICTILISIB; PROGESTERONE RECEPTOR; REGULATOR PROTEIN; SOMATOMEDIN BINDING PROTEIN 4; TAMOXIFEN; TASELISIB; TRANSCRIPTION FACTOR FKHRL1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA, HUMAN; NVP-BYL719; THIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CANCER REGRESSION; CELL CYCLE PROGRESSION; CHEMOSENSITIZATION; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DISEASE MODEL; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; INHIBITION KINETICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RECEPTOR BINDING; RECEPTOR OCCUPANCY; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TUMOR REGRESSION; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CANCER TRANSPLANTATION; CHEMISTRY; DNA MICROARRAY; DRUG RESISTANCE; ENDOPLASMIC RETICULUM; GENETICS; MCF-7 CELL LINE; METABOLISM; METASTASIS; METHODOLOGY; MUTATION; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ENDOPLASMIC RETICULUM; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; MCF-7 CELLS; MICE; MICE, NUDE; MUTATION; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHATIDYLINOSITOL 3-KINASES; RESEARCH DESIGN; SIGNAL TRANSDUCTION; THIAZOLES;

EID: 84928186818     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aav7516     Document Type: Erratum

References (45)

1. J. A. Engelman, J. Luo, L. C. Cantley. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 7, 606-619 (2006).
2. L. C. Cantley. The phosphoinositide 3-kinase pathway. Science 296, 1655-1657 (2002).
3. J. A. Engelman. Targeting PI3K signalling in cancer: Opportunities, challenges and limitations. Nat. Rev. Cancer 9, 550-562 (2009).
4. S. M. Brachmann, K. Ueki, J. A. Engelman, R. C. Kahn, L. C. Cantley. Phosphoinositide 3-kinase catalytic subunit deletion and regulatory subunit deletion have opposite effects on insulin sensitivity in mice. Mol. Cell. Biol. 25, 1596-1607 (2005).
5. L. Zhao, P. K. Vogt. Helical domain and kinase domain mutations in p110a of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc. Natl. Acad. Sci. U.S.A. 105, 2652-2657 (2008).
6. S. Kang, A. G. Bader, P. K. Vogt. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc. Natl. Acad. Sci. U.S.A. 102, 802-807 (2005).
7. Y. Samuels, Z. Wang, A. Bardelli, N. Silliman, J. Ptak, S. Szabo, H. Yan, A. Gazdar, S. M. Powell, G. J. Riggins, J. K. Willson, S. Markowitz, K. W. Kinzler, B. Vogelstein, V. E. Velculescu. High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554 (2004).
8. S. J. Isakoff, J. A. Engelman, H. Y. Irie, J. Luo, S. M. Brachmann, R. V. Pearline, L. C. Cantley, J. S. Brugge. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res. 65, 10992-11000 (2005).
9. D. Juric, J. Rodon, A. M. Gonzalez-Angulo, H. A. Burris, J. Bendell, J. D. Berlin, M. R. Middleton, D. Bootle, M. Boehm, A. Schmitt, N. Rouyrre, C. Quadt, J. Baselga. Abstract CT-01: BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study. Cancer Res. 72, CT-01 (2012).
10. D. Juric, I. Krop, R. K. Ramanathan, J. Xiao, S. Sanabria, T. R. Wilson, Y. Choi, H. Parmar, J. Hsu, J. Baselga, D. D. Von Hoff. Abstract LB-64: GDC-0032, a beta isoform-sparing PI3K inhibitor: Results of a first-in-human phase Ia dose escalation study. Cancer Res. 73, LB-64 (2013).
11. D. Juric, P. Castel, M. Griffith, O. L. Griffith, H. H. Won, H. Ellis, S. H. Ebbesen, B. J. Ainscough, A. Ramu, G. Iyer, R. H. Shah, T. Huynh, M. Mino-Kenudson, D. Sgroi, S. Isakoff, A. Thabet, L. Elamine, D. B. Solit, S. W. Lowe, C. Quadt, M. Peters, A. Derti, R. Schegel, A. Huang, E. R. Mardis, M. F. Berger, J. Baselga, M. Scaltriti. Convergent loss of PTEN leads to clinical resistance to a PI(3)Ka inhibitor. Nature 518, 240-244 (2015).
12. K. E. O'Reilly, F. Rojo, Q. B. She, D. Solit, G. B. Mills, D. Smith, H. Lane, F. Hofmann, D. J. Hicklin, D. L. Ludwig, J. Baselga, N. Rosen. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66, 1500-1508 (2006).
13. A. Carracedo, L. Ma, J. Teruya-Feldstein, F. Rojo, L. Salmena, A. Alimonti, A. Egia, A. T. Sasaki, G. Thomas, S. C. Kozma, A. Papa, C. Nardella, L. C. Cantley, J. Baselga, P. P. Pandolfi. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest. 118, 3065-3074 (2008).
14. V. Serra, M. Scaltriti, L. Prudkin, P. J. Eichhorn, Y. H. Ibrahim, S. Chandarlapaty, B. Markman, O. Rodriguez, M. Guzman, S. Rodriguez, M. Gili, M. Russillo, J. L. Parra, S. Singh, J. Arribas, N. Rosen, J. Baselga. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene 30, 2547-2557 (2011).
15. S. Chandarlapaty, A. Sawai, M. Scaltriti, V. Rodrik-Outmezguine, O. Grbovic-Huezo, V. Serra, P. K. Majumder, J. Baselga, N. Rosen. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19, 58-71 (2011).
16. J. Baselga, M. Campone, M. Piccart, H. A. Burris III, H. S. Rugo, T. Sahmoud, S. Noguchi, M. Gnant, K. I. Pritchard, F. Lebrun, J. T. Beck, Y. Ito, D. Yardley, I. Deleu, A. Perez, T. Bachelot, L. Vittori, Z. Xu, P. Mukhopadhyay, D. Lebwohl, G. N. Hortobagyi. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 366, 520-529 (2012).
17. T. W. Miller, J. M. Balko, E. M. Fox, Z. Ghazoui, A. Dunbier, H. Anderson, M. Dowsett, A. Jiang, R. A. Smith, S. M. Maira, H. C. Manning, A. M. González-Angulo, G. B. Mills, C. Higham, S. Chanthaphaychith, M. G. Kuba, W. R. Miller, Y. Shyr, C. L. Arteaga. ERa-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov. 1, 338-351 (2011).
18. M. M. Morrison, K. Hutchinson, M. M. Williams, J. C. Stanford, J. M. Balko, C. Young, M. G. Kuba, V. Sánchez, A. J. Williams, D. J. Hicks, C. L. Arteaga, A. Prat, C. M. Perou, H. S. Earp, S. Massarweh, R. S. Cook. ErbB3 downregulation enhances luminal breast tumor response to antiestrogens. J. Clin. Invest. 123, 4329-4343 (2013).
19. B. S. Carver, C. Chapinski, J.Wongvipat, H. Hieronymus, Y. Chen, S. Chandarlapaty, V. K. Arora, C. Le, J. Koutcher, H. Scher, P. T. Scardino, N. Rosen, C. L. Sawyers. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19, 575-586 (2011).
20. J. S. Carroll, C. A. Meyer, J. Song, W. Li, T. R. Geistlinger, J. Eeckhoute, A. S. Brodsky, E. K. Keeton, K. C. Fertuck, G. F. Hall, Q. Wang, S. Bekiranov, V. Sementchenko, E. A. Fox, P. A. Silver, T. R. Gingeras, X. S. Liu, M. Brown. Genome-wide analysis of estrogen receptor binding sites. Nat. Genet. 38, 1289-1297 (2006).
21. Cancer Genome Atlas Network, Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012).
22. S. Wee, D. Wiederschain, S. M. Maira, A. Loo, C. Miller, R. deBeaumont, F. Stegmeier, Y. M. Yao, C. Lengauer, PTEN-deficient cancers depend on PIK3CB. Proc. Natl. Acad. Sci. U.S.A. 105, 13057-13062 (2008).
23. M. Elkabets, S. Vora, D. Juric, N. Morse, M. Mino-Kenudson, T. Muranen, J. Tao, A. B. Campos, J. Rodon, Y. H. Ibrahim, V. Serra, V. Rodrik-Outmezguine, S. Hazra, S. Singh, P. Kim, C. Quadt,M. Liu A. Huang, N. Rosen, J. A. Engelman, M. Scaltriti, J. Baselga. mTORC1 inhibition is required for sensitivity to PI3K p110a inhibitors in PIK3CA-mutant breast cancer. Sci. Transl.Med. 5, 196ra199 (2013).
24. J. S. Parker, M. Mullins, M. C. Cheang, S. Leung, D. Voduc, T. Vickery, S. Davies, C. Fauron, X. He, Z. Hu, J. F. Quackenbush, I. J. Stijleman, J. Palazzo, J. S. Marron, A. B. Nobel, E. Mardis, T. O. Nielsen, M. J. Ellis, C. M. Perou, P. S. Bernard. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27, 1160-1167 (2009).
25. S. Massarweh, C. K. Osborne, C. J. Creighton, L. Qin, A. Tsimelzon, S. Huang, H. Weiss, M. Rimawi, R. Schiff. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res. 68, 826-833 (2008).
26. R. L. Yamnik, A. Digilova, D. C. Davis, Z. N. Brodt, C. J. Murphy, M. K. Holz. S6 kinase 1 regulates estrogen receptor a in control of breast cancer cell proliferation. J. Biol. Chem. 284, 6361-6369 (2009).
27. D. Juric, C. Saura, A. Cervantes, C. Kurkjian, M. Patel, J. Sachdev, I. Mayer, I. E. Krop, M. Oliveira, S. Sanabria, S. Cheeti, R. S. Lin, R. A. Graham, T. R. Wilson, H. Parmar, J. Y. Hsu, D. D. Von Hoff, J. Baselga. Ph1b study of the PI3K inhibitor GDC-0032 in combination with fulvestrant in patients with hormone receptor-positive advanced breast cancer, San Antonio Breast Cancer Symposium, San Antonio, TX, 10 to 14 December 2013, abstract PD1-3.
28. F. Janku, D. Juric, J. Cortes, H. Rugo, H. A. Burris, M. Schuler, B. Deschler-Baier, M. R. Middleton, M. Gil-Martin, J. Berlin, E. Winer, D. Bootle, L. Blumenstein, D. Demanse, C. Coughlin, C. Quadt, J. Baselga. Phase I study of the PI3Ka inhibitor BYL719 plus fulvestrant in patients with PIK3CA-altered and wild type ER+/HER2-locally advanced or metastatic breast cancer. J. Clin. Oncol. abstract PD5-5 (2014).
29. I. A. Mayer, V. G. Abramson, S. J. Isakoff, A. Forero, J. M. Balko, M. G. Kuba, M. E. Sanders, J. T. Yap, A. D. Van den Abbeele, Y. Li, L. C. Cantley, E. Winer, C. L. Arteaga. Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptorpositive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol. 32, 1202-1209 (2014).
30. X. Fu, C. J. Creighton, N. C. Biswal, V. Kumar, M. Shea, S. Herrera, A. Contreras, C. Gutierrez, T. Wang, S. Nanda, M. Giuliano, G. Morrison, A. Nardone, K. L. Karlin, T. F. Westbrook, L. M. Heiser, P. Anur, P. Spellman, S. M. Guichard, P. D. Smith, B. R. Davies, T. Klinowska, A. V. Lee, G. B. Mills, M. F. Rimawi, S. G. Hilsenbeck, J. W. Gray, A. Joshi, C. Osborne, R. Schiff. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by cotargeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. Breast Cancer Res. 16, 430 (2014).
31. C. K. Osborne, A. Wakeling, R. I. Nicholson. Fulvestrant: An oestrogen receptor antagonist with a novel mechanism of action. Br. J. Cancer 90 (Suppl. 1), S2-S6 (2004).
32. N. Patani, A. K. Dunbier, H. Anderson, Z. Ghazoui, R. Ribas, E. Anderson, Q. Gao, R. A'Hern, A. Mackay, J. Lindemann, R. Wellings, J. Walker, I. Kuter, L. A. Martin, M. Dowsett. Differences in the transcriptional response to fulvestrant and estrogen deprivation in ER-positive breast cancer. Clin. Cancer Res. 20, 3962-3973 (2014).
33. J. M. Hall, D. P. McDonnell. The estrogen receptor b-isoform (ERb) of the human estrogen receptor modulates ERa transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 140, 5566-5578 (1999).
34. C. García-García, Y. H. Ibrahim, V. Serra, M. T. Calvo, M. Guzmán, J. Grueso, C. Aura, J. Pérez, K. Jessen, Y. Liu, C. Rommel, J. Tabernero, J. Baselga, M. Scaltriti. Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. Clin. Cancer Res. 18, 2603-2612 (2012).
35. G. K. Geiss, R. E. Bumgarner, B. Birditt, T. Dahl, N. Dowidar, D. L. Dunaway, H. P. Fell, S. Ferree, R. D. George, T. Grogan, J. J. James, M. Maysuria, J. D. Mitton, P. Oliveri, J. L. Osborn, T. Peng, A. L. Ratcliffe, P. J. Webster, E. H. Davidson, L. Hood, K. Dimitrov. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat. Biotechnol. 26, 317-325 (2008).
36. A. Prat, J. S. Parker, O. Karginova, C. Fan, C. Livasy, J. I. Herschkowitz, X. He, C. M. Perou. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 12, R68 (2010).
37. Z.Hu, C. Fan, C. Livasy, X.He,D. S. Oh, M. G. Ewend, L.A. Carey, S. Subramanian, R. West, F. Ikpatt, O. I. Olopade, M. van de Rijn, C. M. Perou. A compact VEGF signature associated with distant metastases and poor outcomes. BMC Med. 7, 9 (2009).
38. V. G. Tusher, R. Tibshirani, G. Chu. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. U.S.A. 98, 5116-5121 (2001).
39. A. Subramanian, P. Tamayo, V. K. Mootha, S. Mukherjee, B. L. Ebert, M. A. Gillette, A. Paulovich, S. L. Pomeroy, T. R. Golub, E. S. Lander, J. P. Mesirov. Gene set enrichment analysis: A knowledge knowledgebased approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U.S.A. 102, 15545-15550 (2005).
40. A. Hurtado, K. A. Holmes, C. S. Ross-Innes, D. Schmidt, J. S. Carroll. FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat. Genet. 43, 27-33 (2011).
41. J. M. Gozgit, B. T. Pentecost, S. A. Marconi, R. S. Ricketts-Loriaux, C. N. Otis, K. F. Arcaro. PLD1 is overexpressed in an ER-negative MCF-7 cell line variant and a subset of phospho-Akt-negative breast carcinomas. Br. J. Cancer 97, 809-817 (2007).
42. L. J. van 't Veer, H. Dai, M. J. van de Vijver, Y. D. He, A. A. Hart, M. Mao, H. L. Peterse, K. van der Kooy, M. J.Marton, A. T.Witteveen, G. J. Schreiber, R. M. Kerkhoven, C. Roberts, P. S. Linsley, R. Bernards, S. H. Friend. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536 (2002).
43. J. D. Nelson, O. Denisenko, K. Bomsztyk. Protocol for the fast chromatin immunoprecipitation (ChIP) method. Nat. Protoc. 1, 179-185 (2006).
44. E. Toska, H. A. Campbell, J. Shandilya, S. J. Goodfellow, P. Shore, K. F. Medler, S. G. Roberts. Repression of transcription by WT1-BASP1 requires the myristoylation of BASP1 and the PIP2-dependent recruitment of histone deacetylase. Cell Rep. 2, 462-469 (2012).
45. A. S. Doane, M. Danso, P. Lal, M. Donaton, L. Zhang, C. Hudis, W. L. Gerald. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 25, 3994-4008 (2006).